CNS Webinar Assets - event text-1

    What distinguishes successful schizophrenia clinical development programs from those that do not progress beyond Phase II?


    This live online event will examine approaches to de-risking schizophrenia clinical trials using lessons learned from recent trials as well as new opportunities made possible by AI technology and methodological innovations.

       September 24, 2025

      8AM PDT | 11AM EDT  | 4PM BST  | 5PM CET
    Jeff Lieberman

    Moderated by-1
    Dr. Jeffrey A. Lieberman

     

    Dr. Lieberman, who led the landmark CATIE trial and serves as co-chair of Signant's psychiatry scientific advisory board, will moderate a distinguished panel of CNS experts. Together, they will examine critical factors in study design and methodologies that differentiate successful schizophrenia programs from those that discontinue development.

    Don’t miss this opportunity to gain practical insights about:

    Ensuring patient eligibility and inclusion/exclusion criteria adherence

    Optimizing site selection and investigator training for CNS endpoints

    Enhancing assessment sensitivity and reliability of psychiatric assessment ratings


    Implementing digital measurement solutions


    Addressing placebo response in schizophrenia and CNS studies

    Avoiding pitfalls when transitioning from successful Phase II to Phase III

    Registration Benefits:

    1

    Practical Tips and Strategies:

    Implementable tools for immediate use

    2

    Live Q&A Session:

    Ask the presenters questions and gain insights

    3

    Exclusive Resources:

    Access to post-event materials and recordings

    Meet the Panel

    David Daniel

    David Daniel, MD

    Executive Advisor, Schizophrenia 


    discover.signanthealth.comhs-fshubfsUse- Logo for Promo items-03-1

    •  
    Alan Kott

    Alan Kott, MuDR

    Practice Leader, Data Analytics


    discover.signanthealth.comhs-fshubfsUse- Logo for Promo items-03-1

    •  
    Chris Murphy

    Christopher Murphy, PhD

    Associate Director, Clinical Operations

     

    discover.signanthealth.comhs-fshubfsUse- Logo for Promo items-03-1

    •  

    CNS Webinar Assets - event text-1
    Navigating CNS Clinical Development:
    De-Risking Strategies for Schizophrenia Programs

    Wednesday September 24, 2025  

    8AM PDT | 11AM EDT | 4PM BST | 5PM CET
    REGISTER NOW
    Signant Health Logo

    WHO IS SIGNANT HEALTH

    Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics.

    Learn more at www.signanthealth.com